In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or perhaps the members are not able to tolerate the study drugs. Celastrol was identified to be a Myb inhibitor that suppressed C/EBPβ https://abbv-744cancertreatmentcl13467.bloggerchest.com/31927737/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results